This application proposes to enhance the Paul Calabresi Clinical & Translational Oncology Training Program at the Hollings Cancer Center (HCC) of the Medical University of South Carolina (MUSC) ? referred to as the HCC Calabresi K12 Program. The Hollings Cancer Center is the only NCI-designated cancer center in the State of South Carolina. Development of innovative and impactful clinical and translational research in hematologic and solid tumor malignancies is the top strategic goal for the HCC. Organized into several strong, thematic, interdisciplinary research programs, the HCC has made substantial progress towards this goal. This K12 Program provides the next generation of scientists the opportunity to prepare and expedite the translation of science into the clinic. With new leadership, the HCC is undergoing strategic expansion, with an emphasis on the recruitment and advancement of physician-scientists. While a robust pipeline of cancer focused research training is offered at HCC-MUSC, which spans from high school to undergraduate, graduate and postdoc training opportunities, the HCC Calabresi K12 Program is the only NCI-funded early career faculty development program in South Carolina. As the flagship program, it educates and nurtures junior investigators, called Calabresi Scholars, at the critical juncture prior to transitioning to research independence in a strong culture of team science among cancer investigators encompassing a broad range of disciplines. The program builds on the outstanding strengths of the HCC and MUSC including: 1) a robust infrastructure of shared research resources; 2) a diverse and growing patient population; 3) a NIH funded Clinical and Translational Science Award (CTSA) program with a Master of Science in Clinical Research (MSCR) option; 4) Program Faculty Mentors, comprised of basic and physician scientists, who have well-established track records and funding in collaborative translational research, and 5) a major institutional investment in translational cancer research. The 40 Program Faculty Mentors identified in this application and the Calabresi Scholars constitute the core of patient-oriented research at the HCC.

Public Health Relevance

The Hollings Cancer Center at the Medical University of South Carolina Calabresi K12 Scholars Program reaches across multiple disciplines to develop a cadre of highly trained early career clinician scientists committed to clinical and translational cancer research. Intensive, mentored, interdisciplinary research and career development training helps ensure that there is a diverse pool of independent research- focused scientists equipped to discover and deliver novel therapeutics for effective cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
2K12CA157688-06
Application #
9509040
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Damico, Mark W
Project Start
2013-04-01
Project End
2023-03-31
Budget Start
2018-04-12
Budget End
2019-03-31
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Janz, Tyler A; Kim, Joanne; Hill, Elizabeth G et al. (2018) Association of Care Processes With Timely, Equitable Postoperative Radiotherapy in Patients With Surgically Treated Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg :
Grauzam, St├ęphane; Brock, Amanda M; Holmes, Casey O et al. (2018) NEDD9 stimulated MMP9 secretion is required for invadopodia formation in oral squamous cell carcinoma. Oncotarget 9:25503-25516
Graboyes, Evan M; Kompelli, Anvesh R; Neskey, David M et al. (2018) Association of Treatment Delays With Survival for Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg :
Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704
Majchrzak, Kinga; Nelson, Michelle H; Bowers, Jacob S et al. (2017) ?-catenin and PI3K? inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight 2:
Thaxton, Jessica E; Wallace, Caroline; Riesenberg, Brian et al. (2017) Modulation of Endoplasmic Reticulum Stress Controls CD4+ T-cell Activation and Antitumor Function. Cancer Immunol Res 5:666-675
Carbone, David P; Reck, Martin; Paz-Ares, Luis et al. (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 376:2415-2426
Ellis, Mark A; Graboyes, Evan M; Day, Terry A et al. (2017) Prognostic factors and occult nodal disease in mucoepidermoid carcinoma of the oral cavity and oropharynx: An analysis of the National Cancer Database. Oral Oncol 72:174-178
Ellis, Mark A; Gerry, Daniel R; Neskey, David M et al. (2017) Ewing Sarcoma of the Head and Neck. Ann Otol Rhinol Laryngol 126:179-184
Wrangle, John; Paulos, Chrystal M; Smith Jr, Thomas W et al. (2017) Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer. Mol Ther 25:1995-1996

Showing the most recent 10 out of 25 publications